NCT07646626招募中2 期
A Phase II Study of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.
详细描述
This study includes 2 Parts: Part 1 (SSGJ-705 Plus SSGJ-612 for advanced cancer that have failed standard treatment), and Part 2 (SSGJ-705 or SSGJ-705 Plus SSGJ-612 in combination with chemotherapy for previously untreated advanced gastric cancer).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and/or females over age 18
- •Histologically and/or cytologically documented local advanced or metastatic Colorectal adenocarcinoma (CRC), Urothelial Cancer (UC), Breast Cancer (BC), Biliary Tract Carcinoma(BTC), Gastric/Gastroesophageal Junction Cancer （G/GEJC) , etc.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Expected survival >3 months.
- •Signed informed consent form.
排除标准
- •Any remaining adverse events (AEs) > grade 1 from prior anti-tumor treatment as per Common Terminology Criteria for Adverse Events（CTCAE） v
- •0, with exception of hair loss, fatigue, and grade 2 peripheral neurotoxicity.
- •Pregnant or nursing women or women/men who are ready to give birth
- •symptomatic central nervous system metastasis.
- •Allergy to other antibody drugs or any excipients in the study drugs.
- •Inadequate organ or bone marrow function. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
结局指标
主要结局
Objective response rate (ORR)
时间窗: 12 months
The primary efficacy end point
Incidence of Treatment-Emergent Adverse Events
时间窗: 12 months
The primary safety end point
Severity of Treatment-Emergent Adverse Events
时间窗: 12 months
The primary safety end point
次要结局
- Progression-Free-Survival (PFS)(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax MalariaMalariaNCT07430592R. Kiplin Guy104
招募中
不适用
SSJG-009 Phase II studyMucosal inflammation caused by the physical stimulation of denturesjRCT203125069940
尚未招募
不适用
JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLCNSCLC Harboring EGFR MutationsNCT07714304Huan Zhou20
招募中
1 期
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid TumorsNCT07466160Mabwell (Shanghai) Bioscience Co., Ltd.280
尚未招募
1 期
A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid TumorsSolid TumorMetastatic Ovary CancerMetastatic Gastric CancerMetastatic Endometrial CarcinomaNCT07715747TJ Biopharma Co., Ltd.128